Next Article in Journal
Clinical Application and Utility of Genomic Assays in Early-Stage Breast Cancer: Key Lessons Learned to Date
Previous Article in Journal
Brain Metastases in Non-Small-Cell Lung Cancer: Are Tyrosine Kinase Inhibitors and Checkpoint Inhibitors Now Viable Options?
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Review

Screening for Breast Cancer in 2018—What Should We be Doing Today?

Ottawa Hosp, Dept Med Imaging, Ottawa, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(s1), 115-124; https://doi.org/10.3747/co.25.3770
Received: 2 March 2018 / Revised: 5 April 2018 / Accepted: 11 May 2018 / Published: 1 June 2018
Although screening mammography has delivered many benefits since its introduction in Canada in 1988, questions about perceived harms warrant an up-to-date review. To help oncologists and physicians provide optimal patient recommendations, the literature was reviewed to find the latest guidelines for screening mammography, including benefits and perceived harms of overdiagnosis, false positives, false negatives, and technologic advances. For women 40–74 years of age who actually participate in screening every 1–2 years, breast cancer mortality is reduced by 40%. With appropriate corrections, overdiagnosis accounts for 10% or fewer breast cancers. False positives occur in about 10% of screened women, 80% of which are resolved with additional imaging, and 10%, with breast biopsy. An important limitation of screening is the false negatives (15%–20%). The technologic advances of digital breast tomosynthesis, breast ultrasonography, and magnetic resonance imaging counter the false negatives of screening mammography, particularly in women with dense breast tissue.
Keywords: breast cancer; screening mammography; digital breast tomosynthesis; overdiagnosis breast cancer; screening mammography; digital breast tomosynthesis; overdiagnosis
MDPI and ACS Style

Seely, J.M.; Alhassan, T. Screening for Breast Cancer in 2018—What Should We be Doing Today? Curr. Oncol. 2018, 25, 115-124. https://doi.org/10.3747/co.25.3770

AMA Style

Seely JM, Alhassan T. Screening for Breast Cancer in 2018—What Should We be Doing Today? Current Oncology. 2018; 25(s1):115-124. https://doi.org/10.3747/co.25.3770

Chicago/Turabian Style

Seely, J.M., and T. Alhassan. 2018. "Screening for Breast Cancer in 2018—What Should We be Doing Today?" Current Oncology 25, no. s1: 115-124. https://doi.org/10.3747/co.25.3770

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop